Skip to main content
Caplight Logo









EnGeneIC

EnGeneIC

Private
SydneyHealthcare & Life Scienceshttps://engeneic.com/

Last Round

Crowdfunding

Aug 1, 2021

Total Funding Raised

$17.17M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

EnGeneIC is a clinical-stage biopharmaceutical company that has developed a proprietary nanocell technology for the targeted delivery of chemotherapeutics and functional nucleic acids for cancer treatment.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

nanocell technologytargeted cancer therapydrug delivery platformtargeted drug deliveryimmunotherapynanomedicinecancer nanomedicinecyto-immunotherapybacterially-derived nanocellsdrug delivery vehiclepancreatic cancersolid tumor therapybiologic drug deliveryArmed Nanocell Drug ConjugateANDCsiRNA deliverytheranosticsglioblastoma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

EnGeneIC Comparables

Compare EnGeneIC with similar companies based on industry and business-model similarity.

EnGeneIC comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Vaxiion Therapeutics
79%
Vector Bioscience Cambridge
75%
Actym Therapeutics
69%

EnGeneIC Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
CrowdfundingAug 1, 2021
Series BJan 6, 2015

Key People

Founding team and executive leadership

Jennifer MacDiarmid

Joint-CEO And Director

Executive Team

EnGeneIC Investors

Notable investors and investment history

EnGeneIC investors
InvestorRounds
GRT Capital PartnersSeries B
Foley & Lardner LLPSeries B
VentureCrowdCrowdfunding

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 20, 2026

    Monthly visitors increased 70% MoM.

  • Oct 13, 2025

    Grew 18% QoQ, from 44 to 52 employees.

EnGeneIC Filings

Explore SEC and related filing metadata, where available.

EnGeneIC filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about EnGeneIC's valuation, stock price, and market status.

Is EnGeneIC a public or private company?

EnGeneIC is a private company.

What is the current stock price of EnGeneIC?

EnGeneIC is a private company with no public stock price. No recent secondary market data is available.

How much is EnGeneIC worth (valuation)?

Valuation information for EnGeneIC is not publicly available.

Can I buy EnGeneIC stock?

EnGeneIC shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was EnGeneIC's last funding round?

EnGeneIC's most recent funding round was Crowdfunding on August 1, 2021.

Who are the main investors in EnGeneIC?

Key investors in EnGeneIC include GRT Capital Partners.

Will EnGeneIC IPO soon?

No public IPO plans have been announced for EnGeneIC.

How can I track EnGeneIC secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor EnGeneIC's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSydney
Employee Range38
Year Founded2001
Last FundingAug 1, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?